Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

r-related death in men and women in the U.S., with 160,000 deaths estimated in 2007. Approximately 80 to 85 percent of these patients will be diagnosed with NSCLC, with the majority being diagnosed with locally advanced or metastatic disease.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) in combination with irinotecan for patients who are refractory to irinotecan-based chemotherapy, and as a single agent for patients who are intolerant to irinotecan-based therapy. The effectiveness of ERBITUX for the treatment of EGFR-expressing mCRC cancer is based on obj
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:6/2/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... Vanda,s President and CEO, will deliver a corporate presentation ... New York City on Thursday, June 4, ... presentation at the Jefferies Global Healthcare Conference will be ...
(Date:6/2/2015)... International plc (NASDAQ: ENDP ) (TSX: ENL) (the ... an underwritten public offering of $1.75 billion of ordinary ... are to be sold by Endo. ... the Offering an option, exercisable for a period of ... supplement, to purchase an additional $262.5 million of ordinary ...
(Date:6/2/2015)... STATESVILLE, N.C. , June 2, 2015 ... its Board of Directors declared a quarterly cash dividend ... 26, 2015 to stockholders of record at the close ... About Kewaunee Scientific Founded in 1906, Kewaunee ... design, manufacture, and installation of laboratory, healthcare, and technical ...
Breaking Medicine Technology:Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
(Date:6/2/2015)... Aidan Booth And Steve Clayton's ... yesterday, and has since received rave reviews from ... Tiffany Hendricks has weighed in with her opinion ... on her website HonestyFirstReviews.com. , "These days the ... looking to hone their business skills has gotten ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Food Lion ... its sixth annual “Thriller on the Griller” events, starting ... and South Carolina locations. Each event will raise funds ... to restoring a sense of self, restoring the family ... our military families. , Through these events, Food ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 MEDIA ... Wallace, 571-319-9594 (cell) , Email: ewallace(at)mentalhealthamerica(dot)net , Breaking ... New Mental Health Legislation at MHA Annual Conference ... What: Rep. Murphy to address the Mental Health ... the long-awaited updated version of the Helping Families ...
(Date:6/2/2015)... April 8th, 2015, saw the transformation ... Entertainment’s “RockNRolla Movie Awards” EcoLuxe Lounge, a daylong event, ... of the world’s top providers of ecologically sound and ... by Debbie Durkin, Los Angeles’ leading producer of sustainable ... is a premier red carpet event that makes appearances ...
(Date:6/2/2015)... 2015 On March 19th, 2015, LiveToBeSober.org ... the Hall of Legends at Detroit’s Ford Field. Hosted ... Herman Moore, the goal of the conference was to ... society, highlight the benefits of effective professional rehabilitation programs. ... the options that are available to them in regards ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 3Health News:Congressman Tim Murphy to Unveil Details of New Mental Health Legislation at MHA Annual Conference Thursday 2Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2
... teachers and students prefer enhanced sex education programs//, they ... UK schools. When teen pregnancy is taken into consideration, ... officials said. The study, which was conducted by the ... Medical Journal, covered about 25 secondary schools. ...
... of Parliament tuesday that she would resign if the ... by March 2007. ,Her comment was ... select committee who were apprehensive about the NHS's half-year ... NHS trusts are forecasting deficits. The deficits are expected ...
... over the effects of drinking too much alcohol on their ... While alcohol-related deaths have doubled in last 15 years, just ... last 3 months, worried about the effects of over drinking ... exercise and too much stress – says Legal & General. ...
... type of salmonella bacteria.It is usually found in eggs infected ... bacteria is now found more often in chicken meat. Tests ... increase of salmonella enteritidis on chicken meat., ,Salmonella is ... year with an annual death toll of about 600 in ...
... play an important role in how insects develop from ... model for congestive heart failure// to be effective in ... rhythms, according to UC Davis research published in the ... Academy of Sciences. ,The research, led by cardiologist ...
... includes products like insulin, sugar-free food and healthcare books, ... 'D' Lounge has been set up by Way-to-Health, a ... ,"'D' Lounge offers a complete range of products ... biscuits, jams and honey. Sugar-free toothpaste is also available ...
Cached Medicine News:Health News:Insect Protein Effective for Treating Heart Enlargement, Arrythmias 2
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Medicine Products: